Skip to main content
WRBYWarby Parker Inc.Sell4.5·$26.10+0.38%
SellModerate Confidence
Investment thesis

Warby Parker shows strong price momentum with a technical breakout above all major moving averages and rising volume accumulation, but the stock has already reached its analyst target with negative remaining upside, high short interest of 14%, and a below-average overall score of 4.5 limiting conviction.

Thesis pillars

  • Strong Breakout MomentumImproving
  • Excellent Cash ConversionStable
  • Target Reached Negative AsymmetryStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Warby Parker Inc. (WRBY) Stock Analysis

SellVALUE-TRAP 2/5QualityShortModerate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 7 days (2026-08-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Analyst target reached at $26.10 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk).

Warby Parker designs and sells prescription eyeglasses, sunglasses, contact lenses, and eye care services through 323 U.S. retail stores and digital commerce, with frames starting at $95. Contact lenses contributed 11.1% and eye exams 6.4% of 2025 net revenue; the company... Read more

$26.10+0.8% A.UpsideScore 4.5/10#32 of 32 Medical Instruments & Supplies
QualityF-score7 / 9FCF yield1.01%
Stop $24.21Target $26.23(analyst − 13%)A.R:R 0.1:1
Analyst target$30.15+15.5%13 analysts
$26.23our TP
$26.10price
$30.15mean
$24
$35

Sell if holding. Analyst target reached at $26.10 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.

Passes 5/9 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and earnings proximity 7d<=7d. Suitability: aggressive.

10-K grounded · weekly refresh

About Warby Parker Inc.

About Warby Parker Inc.

Warby Parker operated 323 U.S. retail stores at December 31, 2025, selling eyeglasses, contact lenses (11.1% of 2025 net revenue), and eye exams and vision care (6.4% of 2025 net revenue), with all eyewear regulated by the U.S. FDA as a medical device. The company employed 4,036 people and sold frames starting at $95 in a U.S. eyewear market the Vision Council estimated at $70 billion as of December 2025. Insurance-backed purchases were only 8.3% of 2025 revenue despite insurance covering roughly 60% of industry-wide U.S. vision care purchases.

Warby Parker generates revenue through direct-to-consumer sales of prescription eyewear, contacts, and eye care services across 323 stores and its e-commerce platform. The company designs eyewear in-house at its New York City headquarters and manufactures through a network of more than 30 partners spanning frame factories, lens suppliers, and distribution centers across China, Japan, Vietnam, Italy, and Thailand, with in-house optical labs in Sloatsburg, New York, and Las Vegas, Nevada. The filing flags dependence on a limited number of frame and lens suppliers and reliance on Amazon Web Services for technology infrastructure. Competing against vertically integrated players EssilorLuxottica and VSP (which own frame brands, lens networks, and vision insurance plans) as well as low-priced online rival Zenni Optical, Warby Parker remains underpenetrated in insurance-backed purchases relative to the broader category. Progressive lenses represented 22.3% of prescription units at December 31, 2025, compared with approximately 40% industry-wide, indicating an underpenetrated premium-lens category.

Show full overview

Warby Parker sources frames and lenses from a network of more than 30 manufacturing partners located most notably in China, Japan, Vietnam, Italy, and Thailand, with the Risk Factors Summary explicitly flagging dependence on a limited number of suppliers and contract manufacturers. A loss of any of these partners could negatively affect the business, per the filing. The company also relies on Amazon Web Services for its entire technology infrastructure; the 10-K states that any disruption of or interference with that service could adversely affect business, financial condition, or operations — a single-platform dependency without a named alternative cloud provider.

See also: Healthcare · Medical Instruments & Supplies

From Warby Parker Inc.'s most recent 10-K filing, extracted June 16, 2026.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 20267d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Analyst target reached - limited upside remaining
Earnings in 7 days (event risk)
Weak overall score: 4.5/10

Key Metrics

P/E (TTM)2600.0
P/E (Fwd)39.5
Mkt Cap$3.2B
EV/EBITDA68.1
Profit Mgn0.2%
ROE0.4%
Rev Growth8.3%
Beta1.92
DividendNone
Rating analysts21

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.55bullish
IV113%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMSupplierlimited number of suppliers
    10-K Item 1A: 'We face risks associated with suppliers from whom our products are sourced and are dependent on a limited number of suppliers.'
  • MEDIUMSupplierAmazon Web Services
    10-K Item 1A: 'Our business relies on Amazon Web Services'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.1
Revenue Growth
4.6

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
3.3
Quality Rank
3.8
Growth Rank
4.0

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
1.2
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
Earnings in 7 days
GatesA.R:R 0.1 < 1.5@spotINSIDER 0.64%=HEAVYEARNINGS PROXIMITY 7d<=7dMomentum 4.9<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.9>=4.5No SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
29 · Oversold
20D MA 50D MA 200D MAGOLDEN CROSSSupport $23.50Resistance $30.16

Price Targets

$24
$26
A.Upside+0.8%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (0.8% upside)
! asymmetry at 0.1 (below the engine's 1.5 threshold)@spot
! Insider activity: 0.64%=heavy

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-08-06 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WRBY stock a buy right now?

Sell if holding. Analyst target reached at $26.10 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.21. Score 4.5/10, moderate confidence.

What is the WRBY stock price target?

Take-profit target: $26.23 (+0.8% upside). Prior stop was $24.21. Stop-loss: $24.21.

What are the risks of investing in WRBY?

Analyst target reached - limited upside remaining; Earnings in 7 days (event risk); Weak overall score: 4.5/10.

Is WRBY overvalued or undervalued?

Warby Parker Inc. trades at a P/E of 2600.0 (forward 39.5). TrendMatrix value score: 5.5/10. Verdict: Sell.

What do analysts say about WRBY?

21 analysts cover WRBY with a consensus score of 4.0/5. Average price target: $30.

What does Warby Parker Inc. do?Warby Parker designs and sells prescription eyeglasses, sunglasses, contact lenses, and eye care services through 323...

Warby Parker designs and sells prescription eyeglasses, sunglasses, contact lenses, and eye care services through 323 U.S. retail stores and digital commerce, with frames starting at $95. Contact lenses contributed 11.1% and eye exams 6.4% of 2025 net revenue; the company competes against EssilorLuxottica and VSP in a U.S. eyewear market estimated at $70 billion.

Related stocks: NVST (Envista Holdings Corporation) · STAA (STAAR Surgical Company) · RMD (ResMed Inc.) · TFX (Teleflex Incorporated) · ALGN (Align Technology, Inc.)
Home Stocks WRBY

Latest news

Latest News

StockStory93d ago
MSN86d ago
Newser86d ago
Yahoo Finance84d ago
MSN85d ago
TipRanks85d ago
Marketscreener.com85d agoEarnings
Marketscreener.com85d agoEarnings
IndexBox88d ago
The Globe and Mail90d agoAnalyst
MarketBeat90d agoAnalyst
Cantech Letter94d ago
TradingView87d ago
Insider Monkey84d ago
Yahoo Finance84d ago
Yahoo Finance84d agoEarnings
Investing.com India90d agoAnalyst
Yahoo Finance90d agoProduct
Benzinga31d ago
Benzinga32d ago